Expect New Standard of Care for Elderly Patients With Multiple Myeloma

Dr Marivi Mateos, Hospital Vall d’Hebron, Barcelona, Spain, summarises the promising results from the trial of continuous lenalidomide with low-dose dexamethasone versus current standard of care (melphalan/prednisone/thalidomide [MPT]) for newly diagnosed elderly patients with multiple myeloma (MM).  For relapsed and refractory MM patients, Dr Mateos outlines the promise from the PANORAMA 1 trial of panobinostat, bortezomib, and dexamethasone versus bortezomib and dexamethasone alone. Finally, Dr Mateos updates the European Medical Journal about monoclonal antibodies in MM, such as elotuzumab used alone and in combinations.

Year of Production:
Running Time:


Comments are closed.